Dec. 27 at 1:55 PM
$SCNX [Rezenopy] The Company is trading at an historical support line
$0.5, at/near its ATL. Again-they have secured
$8.0M+ in funding to support ongoing operations (liquidity), successfully launched its first FDA approved drug (Arbli) and remain to-schedule on its second FDA approved drug (Rezenopy) targeting a combined
$500M domestic market. Rezenopy is scheduled to launch in Q1-2026 while Arbli scales. Likely-an RSS will occur here, which will reduce the float considerably and provide a meaningful opportunity to run again. Multiplier upside from this level, as I have highlighted consistently. Two (2) FDA approved drugs, one launched, the second to-schedule,
$500M target markets and additional pipeline drugs under development to 2029.
$8.0M in liquidity obtained, trading at/near an ATL and historical support line. Management has met all milestones over the last 12mos (business pivot, FDA approval (Arbli), IP extension, commercialization/launch Arbli and Rezenopy). Multiplier
